Association of Clinico-demographic Characteristics in the Use of Muscle Relaxant Reversal Agents in a Tertiary Hospital in the Philippines

This retrospective observational study investigated the factors influencing neuromuscular blocking agent (NMBA) reversal agent use at Amang Rodriguez Memorial Medical Center (ARMMC) from June to December 2023. NMBAs facilitate endotracheal intubation, but reversal agents like Sugammadex and Neostigmine are used to prevent complications such as residual neuromuscular blockade. Objectives. This study aimed to determine the prevalence of reversal agent use and identify clinico-demographic characteristics affecting Sugammadex and Neostigmine administration. Data was collected via total enumeration sampling and chart review of 294 patients who underwent general anesthesia. The study examined variables including age, sex, BMI, comorbidities, ASA classification, and the specific muscle relaxant and reversal agent used. Statistical analysis involved descriptive statistics, Chi-square tests, and multivariate logistic regression. Results showed that Sugammadex was used in 69.4% of reversals. Significant associations were found between age and reversal agent choice, with Sugammadex favored in children (p<0.001) and Neostigmine in middle-aged and older patients. Obese patients were more likely to receive Neostigmine (p=0.039). Patients with ASA II or III classifications and comorbidities were more likely to be reversed with Sugammadex (p=0.038). Notably, bronchial asthma was associated with a decreased likelihood of Sugammadex use (OR = 0.12, p = 0.05). This study highlights the influence of patient characteristics on reversal agent selection at ARMMC. The findings can inform the development of local guidelines to optimize NMBA reversal practices and improve patient safety.

NMBA, Reversal Agents, Sugammadex, Neostigmine

1. Bash LD, Turzhitsky V, Black W, Urman RD. Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings. Adv Ther. 2021;38(9):4736. doi:10.1007/S12325-021-01835-2 [Google Scholar] [Crossref]

2. Bash LD, Turzhitsky V, Black W, Urman RD. Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings. Adv Ther. 2021;38(9):4736-4755. doi:10.1007/S12325-021-01835-2/FIGURES/4 [Google Scholar] [Crossref]

3. Cada DJ, Levien TL, Baker DE. Formulary Drug Reviews Sugammadex. Hosp Pharm. 2016;51(7):585-596. doi:10.1310/hpj5107-585 [Google Scholar] [Crossref]

4. Cada DJ, Levien TL, Baker DE. Sugammadex. Hosp Pharm. 2023;51(7):585-596. doi:10.1310/hpj5107-585 [Google Scholar] [Crossref]

5. Colquhoun DA, Vaughn MT, Bash LD, et al. Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study. Br J Anaesth. 2023;130(1):e148-e159. doi:10.1016/J.BJA.2022.04.023 [Google Scholar] [Crossref]

6. Divatia J V., Khan PU, Myatra SN. Tracheal intubation in the ICU: Life saving or life threatening? Indian J Anaesth. 2011;55(5):470. doi:10.4103/0019-5049.89872 [Google Scholar] [Crossref]

7. Dubovoy TZ, Saager L, Shah NJ, et al. Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study from the Multicenter Perioperative Outcomes Group. Anesth Analg. 2020;131(5):1510. doi:10.1213/ANE.0000000000005080 [Google Scholar] [Crossref]

8. Dubovoy TZ, Saager L, Shah NJ, et al. Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study from the Multicenter Perioperative Outcomes Group. Anesth Analg. 2020;131(5):1510. doi:10.1213/ANE.0000000000005080 [Google Scholar] [Crossref]

9. Dubovoy TZ, Saager L, Shah NJ, et al. Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study From the Multicenter Perioperative Outcomes Group. Anesth Analg. 2020;131(5):1510-1519. doi:10.1213/ANE.0000000000005080 [Google Scholar] [Crossref]

10. Flores MM, Singh B. Neuromuscular Blocking Agents. Anesthesia and Analgesia in Laboratory Animals. Published online November 28, 2022:187-201. doi:10.1016/B978-0-12-822215-7.00010-X [Google Scholar] [Crossref]

11. Greco M, Caruso PF, Angelotti G, et al. REVersal of nEuromusculAr bLocking Agents in Patients Undergoing General Anaesthesia (REVEAL Study). J Clin Med. 2023;12(2):563. doi:10.3390/JCM12020563/S1 [Google Scholar] [Crossref]

12. Greco M, Caruso PF, Angelotti G, et al. REVersal of nEuromusculAr bLocking Agents in Patients Undergoing General Anaesthesia (REVEAL Study). J Clin Med. 2023;12(2). doi:10.3390/JCM12020563 [Google Scholar] [Crossref]

13. Hunter JM. Reversal of neuromuscular block. BJA Educ. 2020;20(8):259. doi:10.1016/J.BJAE.2020.03.008 [Google Scholar] [Crossref]

14. Jain A, Wermuth HR, Dua A, Singh K, Maani C V. Rocuronium. xPharm: The Comprehensive Pharmacology Reference. Published online July 6, 2023:1-5. doi:10.1016/B978-008055232-3.62554-1 [Google Scholar] [Crossref]

15. Jain A, Wermuth HR, Dua A, Singh K, Maani C V. Rocuronium. xPharm: The Comprehensive Pharmacology Reference. Published online July 6, 2023:1-5. doi:10.1016/B978-008055232-3.62554-1 [Google Scholar] [Crossref]

16. Jiang R, Horvath B. Neostigmine. The Essence of Analgesia and Analgesics. Published online August 8, 2023:479-481. doi:10.1017/CBO9780511841378.120 [Google Scholar] [Crossref]

17. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine. Anesthesiology. 2008;109(5):816-824. doi:10.1097/ALN.0B013E31818A3FEE, [Google Scholar] [Crossref]

18. Korkmaz MO, Sayhan H, Guven M. Does sugammadex decrease the severity of agitation and complications in pediatric patients undergoing adenotonsillectomy? Saudi Med J. 2019;40(9):907. doi:10.15537/SMJ.2019.9.24485 [Google Scholar] [Crossref]

19. Lundstrøm LH, Duez CHV, Nørskov AK, et al. Effects of avoidance or use of neuromuscular blocking agents on outcomes in tracheal intubation: a Cochrane systematic review. Br J Anaesth. 2018;120(6):1381-1393. doi:10.1016/J.BJA.2017.11.106 [Google Scholar] [Crossref]

20. Maher T. Chapter 16: Anesthetic Agents: General and Local Anesthetics. In: Lippincott Williams & Wilkins. [Google Scholar] [Crossref]

21. Martin-Flores M, Basher KL. Neuromuscular Blockade. Advanced Monitoring and Procedures for Small Animal Emergency and Critical Care: Second Edition. Published online November 13, 2023:691-698. doi:10.1002/9781119581154.ch52 [Google Scholar] [Crossref]

22. Martini CH, Honing GHM, Bash LD, et al. The Use of Muscle Relaxants and Reversal Agents in a Setting Without Cost Restrictions: Experience from a Tertiary Academic Hospital in the Netherlands. Ther Clin Risk Manag. 2022;18:379. doi:10.2147/TCRM.S350314 [Google Scholar] [Crossref]

23. Naguib M, Lien CA. Chapter 13-Pharmacology of Muscle Relaxants and Their Antagonists. [Google Scholar] [Crossref]

24. Oh MY, Chai YJ, Huang TY, et al. Administration of neostigmine after tracheal intubation shortens time to successful intraoperative neuromonitoring during thyroid surgery: a randomized controlled trial. Sci Rep. 2022;12(1):16797. doi:10.1038/S41598-022-21282-5 [Google Scholar] [Crossref]

25. Pani N, Dongare PA, Mishra RK. Reversal agents in anaesthesia and critical care. Indian J Anaesth. 2015;59(10):664. doi:10.4103/0019-5049.167484 [Google Scholar] [Crossref]

26. Plaud B, Baillard C, Bourgain JL, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020;39(1):125-142. doi:10.1016/J.ACCPM.2020.01.005 [Google Scholar] [Crossref]

27. Renew JR, Ratzlaff R, Hernandez-Torres V, Brull SJ, Prielipp RC. Neuromuscular blockade management in the critically Ill patient. Journal of Intensive Care 2020 8:1. 2020;8(1):1-15. doi:10.1186/S40560-020-00455-2 [Google Scholar] [Crossref]

28. Ritz ML, Derian A. Atracurium. xPharm: The Comprehensive Pharmacology Reference. Published online August 14, 2023:1-4. doi:10.1016/B978-008055232-3.61265-6 [Google Scholar] [Crossref]

29. Rodney G, Raju P, Belford I. Should neuromuscular blocking agents always be used? Response to Br J Anaesth 2018; 120: 1150–3. Br J Anaesth. 2019;122(1):e8-e9. doi:10.1016/j.bja.2018.09.013 [Google Scholar] [Crossref]

30. Smith G, D’Cruz JR, Rondeau B, Goldman J. General Anesthesia for Surgeons. StatPearls. Published online August 5, 2023. Accessed January 31, 2024. https://www.ncbi.nlm.nih.gov/books/NBK493199/ [Google Scholar] [Crossref]

31. Yip PC, Hannam JA, Cameron AJD, Campbell D. Incidence of residual neuromuscular blockade in a post-anaesthetic care unit. Anaesth Intensive Care. 2010;38(1):91-95. doi:10.1177/0310057X1003800116 [Google Scholar] [Crossref]

• Measuring Waste of Patient Time in Health Care at Non-Digitized Hospital: An Observational Study in Bangabandhu Sheikh Mujib Medical University, Bangladesh
• Reaffirming Clinical Confidence in Atorvastatin Therapy: A Digital Outreach Case Study from Tamil Nadu, India
• Clinical Manifestations and Therapeutic Response in a Patient with Hypothyroidism: A Case Report
• Eranda (Ricinus Communis) In Gridhrasi (Sciatica): Classical Rationale, Pharmacology and Clinical Evidence- A Narrative Literature Review
• Magnetotherapy in Pain Management: Mechanisms, Clinical Applications, and Future Perspectives – A Review